

**Virginia's Department of Medical Assistance Services
Pharmacy and Therapeutics Committee Meeting**

*600 East Broad Street – 7th Floor Conference Rooms
Richmond, Virginia 23219*

Thursday, September 15, 2022 - 10:00 a.m.

Welcome and Comments from DMAS' Director

Chethan Bachireddy, MD, CMO, Chair

Call to Order

Chethan Bachireddy, MD, CMO, Chair

Drug Utilization Review (DUR) Board Update

Rachel Cain, PharmD

Approval of Minutes from March 17, 2022, Meeting

P&T Committee Members

PDL Management

P&T Committee Members

Old business

- Physician Administered Drugs
- Bylaws

Phase II – New Drug Review (Therapeutic Class)

Brand Drugs

- Twynéo[®] topical (Acne Agents, Topical)
- Zimhi[™] (Opiate Dependence Treatments) (closed)
- Epsolay[®] (Rosacea Agents, Topical)
- Fleqsuvy[™] & Lyvispah[™] (Skeletal Muscle Relaxants)

Generics Drugs and New Dosage Forms

- tramadol Solution; generic (AG) for Qdolo[®] (Analgesics, Narcotics Short)
- insulin glargine Solostar generic Lantus[®] Solostar and insulin glargine generic for Lantus[®] (Insulin And Related Agents)
- diclofenac 2% topical sol generic Pennsaid[®] and diclofenac potassium generic Zipsor[™] (NSAIDS)
- naloxone HCL 4 mg nasal spray generic Narcan[®] (Opiate Dependence Treatments)

Potential New PDL Closed Classes

- Glucagon Agents (Potential new PDL Closed Class)
- Hemophilia Treatment (Potential new PDL Closed Class)
- Sickle Cell Anemia Treatments (Potential new PDL Closed Class)
- Weight Management Agents (Potential new PDL Closed Class)

PDL Phase I – Annual Review -

Antibiotics/Anti-Infectives

- Antibiotics, Vaginal

Antivirals

- Hepatitis C Agents (*Closed Class*)
- HIV (*Closed Class*)

Cardiac Medications

- Angiotensin Modulators II (includes Direct Renin Inhibitors & combination products)
- Calcium Channel Blockers (includes dihydropyridine and non-dihydropyridine agents)
- Lipotropics, Other (includes Bile Acid Sequestrants, Cholesterol Absorption Inhibitor agents, Fibrin Acid derivatives, Microsomal Triglyceride Transfer Protein Inhibitors, Niacin derivatives, Oligonucleotide Inhibitors and Omega 3 agents)
- Pulmonary Arterial Hypertension Agents, Oral/Inhaled/Injectable (includes Endothelin-1 agents, PDE-5 Inhibitors, Prostacyclin analogues, Prostacyclin Vasodilator, Soluble Guanylate Cyclase Stimulators)

Central Nervous System

- Alzheimer's Agents
- Anticonvulsants (*Closed class*)
- Antidepressants, SSRI
- Antipsychotics (includes oral and long acting injectables) (*Closed Class*)
- Sedative Hypnotics

Dermatitis

- Immunomodulators, Atopic Dermatitis (*Closed Class*)

Ophthalmic

- Allergic Conjunctivitis (includes Ophthalmic Antihistamines & Mast Cell Stabilizers)
- Antibiotics
- Antibiotic/Steroid Combinations
- Anti-Inflammatory Agents (includes Ophthalmic NSAIDS & Corticosteroids)

Respiratory

- Cough & Cold Agents (*Legend*)
- Glucocorticoids (*includes nebulized solutions, metered dose inhalers and combinations*) (*Closed Class*)
- Intranasal Rhinitis (includes Antihistamines and Corticosteroids)

Classes reviewed by DMAS with no significant changes

Blood Modifiers

- Bile Acid Salts
- Phosphate Binders

Cardiac Medications

- Angiotensin Modulator Combinations
- Antihypertensives, Sympatholytics (*Closed Class*)
- Beta Blockers (includes combination products)
- Lipotropics, Statins

Central Nervous System

- Antidepressants, Other
- Movement Disorders (Closed Class)

Dermatitis

- Steroids, Topical

Endocrine & Metabolic Agents Oral

- Glucocorticoids, Oral
- Growth Hormones (Closed Class)
- HAE Treatments
- Progestins for Cachexia

Gastrointestinal

- Antiemetic/Antivertigo Agents
- GI Motility, Chronic
- H. pylori Agents
- Histamine II Receptor Antagonists
- Proton Pump Inhibitors
- Ulcerative Colitis

Genitourinary

- Bladder Relaxants
- BPH Agents

Ophthalmic

- Ophthalmic, Anti-Inflammatory/Immunomodulator (Closed Class)
- Ophthalmic, Glaucoma

Respiratory

- Anti-Allergens, Oral
- Antibiotics, Inhaled
- Antihistamines, Minimally Sedating
- Bronchodilators, Beta Agonist
 - Bronchodilators, Long-Acting Beta Adrenergics
 - Bronchodilators, Short Acting Beta Adrenergics
- COPD Agents (Closed)
- Epinephrine, Self-Injected
- Leukotriene Modifiers

Confidential Meeting (Pricing Information Discussion)

P&T Committee Members & DMAS Staff

PDL Recommendations and Vote

P&T Committee Members

Criteria Discussion of Phase II New Drugs*

P&T Committee Members

Criteria Discussion of PDL Phase I Drug Classes*

P&T Committee Members

Next Meeting - tentatively scheduled for March 16, 2023